Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience ...
Sanofi and SK bioscience expand collaboration to develop next-gen PCVs, including PCV21, the first 21-valent vaccine in phase 3 for infants & toddlers, aiming to address unmet needs in pneumococcal disease.
Related News
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience ...
Sanofi and SK bioscience expand collaboration to develop next-gen PCVs, including PCV21, the first 21-valent vaccine in phase 3 for infants & toddlers, aiming to address unmet needs in pneumococcal disease.